Characterization of Pyroptosis-Related Subtypes RNA-Seq and ScRNA-Seq to Predict Chemo-Immunotherapy Response in Triple-Negative Breast Cancer

Overview

Journal Front Genet

Date 2022 Apr 7

PMID 35386285

Authors

Chenlu Li

Jingjing Pan

Yinyan Jiang

Yanzhi Wu

Zhenlin Jin

Xupeng Chen

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is associated with poor prognosis and invalid therapeutical response to immunotherapy due to biological heterogeneity. There is an urgent need to screen for reliable indices, especially immunotherapy-associated biomarkers that can predict patient outcomes. Pyroptosis, as an inflammation-induced type of programmed cell death, is shown to create a tumor-suppressive environment and improve the chemotherapeutic response in multiple tumors. However, the specific therapeutic effect of pyroptosis in TNBC remains unclear. In this study, we present a consensus clustering by pyroptosis-related signatures of 119 patients with TNBC into two subtypes (clusterA and clusterB) with distinct immunological and prognostic characteristics. First, clusterB, associated with better outcomes, was characterized by a significantly higher pyroptosis-related signature expression, tumor microenvironment prognostic score, and upregulation of immunotherapy checkpoints. A total of 262 differentially expressed genes between the subtypes were further identified and the Ps-score was built using LASSO and COX regression analyses. The external GEO data set demonstrated that cohorts with low Ps-scores consistently had higher expression of pyroptosis-related signatures, immunocyte infiltration levels, and better prognosis. In addition, external immunotherapy and chemotherapy cohorts validated that patients with lower Ps-scores exhibited significant therapeutic response and clinical benefit. Combined with other clinical characteristics, we successfully constructed a nomogram to effectively predict the survival rate of patients with TNBC. Finally, using the scRNA-seq data sets, we validated the landscape of cellular subtypes of TNBC and successfully constructed an miRNA-Ps-score gene interaction network. These findings indicated that the systematic assessment of tumor pyroptosis and identification of Ps-scores has potential clinical implications and facilitates tailoring optimal immunotherapeutic strategies for TNBC.

Citing Articles

Pyroptosis Induction with Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with PD-L1 Blockade Boosts Efficacy against Liver Cancer.

Zhang N, Zeng W, Xu Y, Li R, Wang M, Liu Y Adv Healthc Mater. 2023; 13(7):e2302606.

PMID: 37987462 PMC: 10939858. DOI: 10.1002/adhm.202302606.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Zaki M, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti T . IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010; 185(8):4912-20. PMC: 3104023. DOI: 10.4049/jimmunol.1002046. View

Wu J, Cai Y, Zhao G, Li M . A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer. J Clin Lab Anal. 2021; 35(6):e23779. PMC: 8183938. DOI: 10.1002/jcla.23779. View

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R . Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018; 36(5):411-420. PMC: 6700744. DOI: 10.1038/nbt.4096. View

Nolan E, Savas P, Policheni A, Darcy P, Vaillant F, Mintoff C . Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. Sci Transl Med. 2017; 9(393). PMC: 5822709. DOI: 10.1126/scitranslmed.aal4922. View

Pohl S, Brook N, Agostino M, Arfuso F, Kumar A, Dharmarajan A . Wnt signaling in triple-negative breast cancer. Oncogenesis. 2017; 6(4):e310. PMC: 5520491. DOI: 10.1038/oncsis.2017.14. View

Karki R, Kanneganti T . Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019; 19(4):197-214. PMC: 6953422. DOI: 10.1038/s41568-019-0123-y. View

Yang F, Cao L, Sun Z, Jin J, Fang H, Zhang W . Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors. Int J Biol Sci. 2016; 12(12):1568-1577. PMC: 5166497. DOI: 10.7150/ijbs.16874. View

10.

Sullivan L, Massaro J, DAgostino Sr R . Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004; 23(10):1631-60. DOI: 10.1002/sim.1742. View

11.

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

12.

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

13.

Liu L, Zhao H, Ma T, Ge F, Chen C, Zhang Y . Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection. PLoS One. 2015; 10(1):e0117058. PMC: 4305315. DOI: 10.1371/journal.pone.0117058. View

14.

Reisenbichler E, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K . Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol. 2020; 33(9):1746-1752. PMC: 8366569. DOI: 10.1038/s41379-020-0544-x. View

15.

Wang Z, Milne K, Derocher H, Webb J, Nelson B, Watson P . PD-L1 and intratumoral immune response in breast cancer. Oncotarget. 2017; 8(31):51641-51651. PMC: 5584276. DOI: 10.18632/oncotarget.18305. View

16.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

17.

Carithers L, Moore H . The Genotype-Tissue Expression (GTEx) Project. Biopreserv Biobank. 2015; 13(5):307-8. PMC: 4692118. DOI: 10.1089/bio.2015.29031.hmm. View

18.

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

19.

Chen L, Wang L, Tsang N, Ojcius D, Chen C, OuYang C . Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4(12):1276-93. PMC: 3531603. DOI: 10.1002/emmm.201201569. View

20.

Giuli M, Giuliani E, Screpanti I, Bellavia D, Checquolo S . Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype. J Oncol. 2019; 2019:8707053. PMC: 6657611. DOI: 10.1155/2019/8707053. View